Officer exercised or converted 9,326 HALO derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Nov 1, 2025
- Reporting period
- Not applicable
- Filed with the SEC
- Dec 19, 2025
OfficerOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001159036-25-000075
Filed / recordedDec 19, 2025, 10:39 PM UTCAdded to OQROOct 6, 2026, 7:59 PM UTC Data qualityVerified: identifiers matched exactly IssuerHALOZYME THERAPEUTICS, INC. Reporting personCortney Caudill Officer titleSVP, CHIEF OPERATING OFFICER SecurityRestricted Stock Units TableDerivative (Table II) Transaction dateNov 1, 2025 Acquired / disposedDisposed (D) Footnotes from the filing
- This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Around the same time
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Director sold ~$141K of Halozyme
Scheduled in advance